Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression

Shock

Volumn 43, Issue 4, 2015, Pages 334-343

  Shindo, Yuichiro ^a,b   Unsinger, Jacqueline ^a   Burnham, Cary Ann ^a   Green, Jonathan M ^a   Hotchkiss, Richard S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

Adaptive immunity; Candida; Endotoxin; Innate immunity; Shock

Indexed keywords

CD28 ANTIGEN; CELL ADHESION MOLECULE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; KI 67 ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PROGRAMMED CELL DEATH 1 ANTIBODY; RECOMBINANT INTERLEUKIN 7; UNCLASSIFIED DRUG; IL7 PROTEIN, HUMAN; INTERLEUKIN 7; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT PROTEIN; VERY LATE ACTIVATION ANTIGEN 4;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEPSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CANDIDIASIS; CYTOLOGY; DISEASE MODEL; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PATHOPHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; CANDIDA ALBICANS; CANDIDIASIS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSION; INTEGRIN ALPHA4BETA1; INTERFERON-GAMMA; INTERLEUKIN-7; LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; LYMPHOCYTES; MALE; MICE; MICE, INBRED C57BL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECOMBINANT PROTEINS; SEPSIS;

EID: 84924976132     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000317     Document Type: Article

References (41)

1. Martin GS, Mannino DM, Moss M: The effect of age on the development and outcome of adult sepsis. Crit Care Med 34(1):15-21, 2006.
2. Kung HC, Hoyert DL, Xu J, Murphy SL: Deaths: final data for 2005. Natl Vital Stat Rep 56(10):1-120, 2008.
3. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 13(3):260-268, 2013.
4. Angus DC, van der Poll T: Severe sepsis and septic shock. N Engl J Med 369(9):840-851, 2013.
5. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13(12): 862-874, 2013.
6. Kasten KR, Tschop J, Adediran SG, Hildeman DA, Caldwell CC: T cells are potent early mediators of the host response to sepsis. Shock 34(4):327-336, 2010.
7. Sherwood ER, Hotchkiss RS: BTLA as a biomarker and mediator of sepsis-induced immunosuppression. Crit Care 17(6):1022, 2013.
8. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A: The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 20(4):224-233, 2014.
9. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS: Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. J Leukoc Biol 88(2):233-240, 2010.
10. Chang KC, Burnham CA, Compton SM, Rasche DP, Mazuski R, Smcdonough J, Unsinger J, Korman AJ, Green JM, Hotchkiss RS: Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 17(3):R85, 2013.
11. Unsinger J, Burnham CA, McDonough J, Morre M, Prakash PS, Caldwell CC, Dunne WM Jr, Hotchkiss RS: Interleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis. J Infect Dis 206(4):606-616, 2012.
12. Kasten KR, Prakash PS, Unsinger J, Goetzman HS, England LG, Cave CM, Seitz AP, Mazuski CN, Zhou TT, Morre M, et al.: Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun 78(11):4714-4722, 2010.
13. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS, et al.: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A 106(15):6303-6308, 2009.
14. Venet F, Foray AP, Villars-Mechin A, Malcus C, Poitevin-Later F, Lepape A, Monneret G: IL-7 restores lymphocyte functions in septic patients. J Immunol 189(10):5073-5081, 2012.
15. Mackall CL, Fry TJ, Gress RE: Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 11(5):330-342, 2011.
16. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, et al.: Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 55(2):291-300, 2012.
17. Seo YB, Im SJ, Namkoong H, Kim SW, Choi YW, Kang MC, Lim HS, Jin HT, Yang SH, Cho ML, et al.: Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol 88(16):8998-9009, 2014.
18. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC, Silini EM, Andreone P, Missale G, et al.: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138(2):682-693, 693 e1-4, 2010.
19. + lymphocytopenia. J Antimicrob Chemother 65(12):2697-2698, 2010.
20. Declerck S, Vansteenkiste J: Immunotherapy for lung cancer: ongoing clinical trials. Future Oncol 10(1):91-105, 2014.
21. Inoue S, Bo L, Bian J, Unsinger J, Chang K, Hotchkiss RS: Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36(1):38-44, 2011.
22. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al.: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369(2):122-133, 2013.
23. Hotchkiss RS, Moldawer LL: Parallels between cancer and infectious disease. N Engl J Med 371(4):380-383, 2014.
24. Davis CG, Chang K, Osborne D, Walton AH, Dunne WM, Muenzer JT: Increased susceptibility to Candida infection following cecal ligation and puncture. Biochem Biophys Res Commun 414(1):37-43, 2011.
25. Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, et al.: IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol 184(7):3768-3779, 2010.
26. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G: Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 25(4):477-483, 2013.
27. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H, Bienvenu J, Gueyffier F, Vanhems P: Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32(8):1175-1183, 2006.
28. Vivar N, Ruffin N, Sammicheli S, Hejdeman B, Rethi B, Chiodi F: Survival and proliferation of CD28- T cells during HIV-1 infection relate to the amplitude of viral replication. J Infect Dis 203(11):1658-1667, 2011.
29. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP, Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27(7):1230-1251, 1999.
30. Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1(3):199-206, 1990.
31. Wohler J, Bullard D, Schoeb T, Barnum S: LFA-1 is critical for regulatory T cell homeostasis and function. Mol Immunol 46(11-12):2424-2428, 2009.
32. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER: Diminished bacterial clearance is associated with decreased IL-12 and interferon-gamma production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21(5):415-425, 2004.
33. Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators: Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 39(4):665-670, 2011.
34. Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, Monneret G, Venet F, Bleeker-Rovers CP, van de Veerdonk FL, et al.: Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis 14:166, 2014.
35. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T: A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14(12):1212-1218, 2013.
36. Keir ME, Butte MJ, Freeman GJ, Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704, 2008.
37. Manukyan MC, Weil BR, Wang Y, Abarbanell AM, Herrmann JL, Poynter JA, Meldrum DR: The phosphoinositide-3 kinase survival signaling mechanism in sepsis. Shock 34(5):442-449, 2010.
38. Shi L, Chen S, Yang L, Li Y: The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 6(1):74, 2013.
39. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8(3):239-245, 2007.
40. Salomao R, Brunialti MK, Rapozo MM, Baggio-Zappia GL, Galanos C, Freudenberg M: Bacterial sensing, cell signaling, and modulation of the immune response during sepsis. Shock 38(3):227-242, 2012.
41. Bryant-Hudson KM, Carr KM: PD-L1Yexpressing dendritic cells contribute to viral resistance during acute HSV-1 infection. Clin Dev Immunol 2012:924619, 2012.